Latest Ratios: P/E Ratio -152.3x · EV/EBITDA 13.5x · ROE -0.8%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $707M | $468M | $392M | $516M | $659M | — | — |
| Enterprise Value | $1.2B | $925M | $933M | $1.1B | $1.3B | — | — |
| P/E Ratio → | -152.32 | — | — | — | 10.53 | — | — |
| P/S Ratio | 0.67 | 0.44 | 0.38 | 0.49 | 0.62 | — | — |
| P/B Ratio | 1.24 | 0.83 | 0.71 | 0.74 | 0.85 | — | — |
| P/FCF | 10.74 | 7.12 | 8.27 | 11.50 | 9.03 | — | — |
| P/OCF | 10.00 | 6.62 | 7.66 | 10.67 | 8.23 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.87 | 0.90 | 1.05 | 1.18 | — | — |
| EV / EBITDA | 13.48 | 10.72 | — | — | 58.41 | — | — |
| EV / EBIT | 18.23 | 26.12 | — | — | — | — | — |
| EV / FCF | — | 14.05 | 19.69 | 24.48 | 17.28 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 46.9% | 46.9% | 48.7% | 48.8% | 50.9% | 53.6% | 50.1% |
| Operating Margin | 6.0% | 6.0% | -11.1% | -4.5% | -1.1% | 12.9% | 9.5% |
| Net Profit Margin | -0.4% | -0.4% | -15.1% | -7.7% | -3.8% | 10.0% | 7.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -0.8% | -0.8% | -24.9% | -10.9% | -3.6% | 7.7% | 5.4% |
| ROA | -0.4% | -0.4% | -11.7% | -5.4% | -2.5% | 6.7% | 4.6% |
| ROIC | 4.5% | 4.5% | -7.3% | -2.7% | -0.6% | 7.3% | 5.5% |
| ROCE | 6.0% | 6.0% | -9.6% | -3.5% | -0.8% | 9.3% | 6.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.89 | 0.89 | 1.03 | 0.87 | 0.81 | 0.04 | 0.04 |
| Debt / EBITDA | 5.79 | 5.79 | — | — | 28.94 | 0.32 | 0.35 |
| Net Debt / Equity | — | 0.81 | 0.98 | 0.83 | 0.78 | 0.03 | 0.01 |
| Net Debt / EBITDA | 5.29 | 5.29 | — | — | 27.88 | 0.29 | 0.08 |
| Debt / FCF | — | 6.94 | 11.42 | 12.98 | 8.25 | 0.43 | 0.55 |
| Interest Coverage | 1.04 | 1.04 | -2.68 | -1.10 | -0.70 | 494.33 | 20.27 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.63 | 1.63 | 1.53 | 1.53 | 1.59 | 1.31 | 1.44 |
| Quick Ratio | 1.63 | 1.63 | 1.53 | 1.53 | 1.59 | 1.31 | 1.44 |
| Cash Ratio | 0.35 | 0.35 | 0.23 | 0.20 | 0.17 | 0.04 | 0.30 |
| Asset Turnover | — | 0.91 | 0.84 | 0.73 | 0.70 | 0.64 | 0.67 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 49.58 | 52.63 | 57.46 | 54.86 | 54.26 | 46.21 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 99.3% | — | — |
| Payout Ratio | — | — | — | — | — | 138.7% | 192.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 9.5% | — | — |
| FCF Yield | 9.3% | 14.0% | 12.1% | 8.7% | 11.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 99.3% | — | — |
| Shares Outstanding | — | $51M | $50M | $50M | $50M | $4M | $4M |
Includes 30+ ratios · 6 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EHAB stock.
Enhabit, Inc.'s current P/E ratio is -152.3x. The historical average is 10.5x.
Enhabit, Inc.'s current EV/EBITDA is 13.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.6x.
Enhabit, Inc.'s return on equity (ROE) is -0.8%. The historical average is -4.5%.
Based on historical data, Enhabit, Inc. is trading at a P/E of -152.3x. Compare with industry peers and growth rates for a complete picture.
Enhabit, Inc. has 46.9% gross margin and 6.0% operating margin.
Enhabit, Inc.'s Debt/EBITDA ratio is 5.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Medicare Advantage reimbursement compression
Metrics are mathematically derived from official filings.
Market Skepticism Reflects Execution Risk
According to current market data, Enhabit trades at a forward P/E of 23.00, which, when compared to the broader healthcare services sector, suggests that investors are pricing in significant uncertainty regarding the company's ability to stabilize margins following its transition to a standalone public entity.
The valuation discount relative to peers like Addus HomeCare implies that the market remains unconvinced by the current turnaround narrative. Investors should monitor whether the forward earnings multiple can be sustained if the company fails to demonstrate consistent margin expansion in upcoming quarters.
Capital Efficiency Remains Under Pressure
Based on reported financial statements, Enhabit's ROIC has struggled to maintain positive momentum, fluctuating between a low of -6.1% in 2024Q3 and a modest 2.2% in 2026Q1, indicating that the company is currently failing to generate returns that exceed its cost of capital.
The persistent weakness in return on invested capital suggests that the company's asset base, heavily weighted toward goodwill, is not being utilized efficiently to drive incremental earnings. This trend warrants further investigation into whether the current clinical labor model can ever achieve the scale necessary to deliver competitive shareholder returns.
Working Capital Cycles Signal Constraints
As evidenced by recent quarterly filings, Enhabit's asset turnover ratio has remained stagnant at approximately 0.23, highlighting the operational difficulty of converting a large, fixed-cost clinical footprint into higher revenue volume in a competitive and increasingly price-sensitive home health market.
The stability of the DSO around 50-55 days suggests that while collection processes are consistent, the company lacks the leverage to accelerate cash conversion. This lack of efficiency in working capital management limits the company's ability to self-fund growth initiatives without relying on external financing.
Debt Discipline Amidst Margin Volatility
According to historical balance sheet data, Enhabit has maintained a conservative debt-to-equity ratio of 0.82 as of 2026Q1, demonstrating a disciplined approach to capital structure that provides a necessary buffer against the company's recent periods of negative operating margins and cash flow instability.
While the debt load is manageable, the interest coverage ratio remains highly sensitive to earnings volatility, as seen in the negative coverage periods during 2024. Investors should monitor whether this conservative leverage profile is sufficient to support the company through potential future reimbursement shocks.
Misapplication of P/E Multiples
As reported in financial analysis, the P/E ratio is frequently misapplied to Enhabit, as the company's significant non-cash charges and restructuring costs render GAAP earnings a poor indicator of the underlying cash-generating capacity of its hospice and home health segments.
Analysts should instead focus on EV/EBITDA or free cash flow yield to better understand the company's operational performance. Relying on P/E multiples in this context obscures the true value of the company's hospice licenses and the impact of labor-related margin compression.